FDA approves first generic versions of Zyprexa

October 24, 2011

(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Zyprexa posted sales of $5.7 billion last year for drugmaker Eli Lilly & Co Inc., according to prescription tracking company IMS Health.

The new low-cost versions of the drug will be marketed by Indian generic drugmaker Dr. Reddy's Laboratories and by Teva Pharmaceutical Industries, based in Israel.

Zyprexa is part of a class of medications called atypical antipsychotics that effect levels of dopamine, a brain chemical that controls behavior, mood and movement. Doctors overwhelmingly embraced the drugs in the 1990s over older treatments, because they were thought to be less likely to cause side effects like muscle tremors and spasms. The newer medications have their own side effects; including weight gain, high blood sugar and drowsiness.

Drugs like Zyprexa can cost up to $500 per month. Generic versions can cut the cost by up to 80 percent.

FDA approves of medications after the patent on the original drug expires or has been ruled invalid in court.

Shares of Indianapolis-based Eli Lilly rose 12 cents to $38.19 in afternoon trading.

Explore further: Americans turn to generic medications in 2010: report

shares

Related Stories

Americans turn to generic medications in 2010: report

April 22, 2011

(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Recommended for you

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.